Biofunctionalized nanoparticles: an emerging drug delivery platform for various disease treatments.
Biological barriers, such as phagocytosis and nonspecific distribution, are major factors limiting the clinical translation of nanomedicine. Biomimetic and bioengineering strategies have been used to overcome these challenges. In particular, natural cell membrane-based biofunctionalized nanoparticles (CMFNPs) have gained widespread attention owing to their cell surface mimetic characteristics and tailored nanomaterial features. These hybrid nanocarriers show strong potential for the delivery of myriad therapeutic agents. Herein, we highlight the most recent advances in CMFNP-based drug delivery systems and address the challenges and opportunities in the field.
School of Integrative Engineering, Chung-Ang University, Seoul, Republic of Korea; Department of Biomedical Science, College of Life Science, CHA University, Republic of Korea.
Rajendran J C
RJ
Bose
Department of Biomedical Science, College of Life Science, CHA University, Republic of Korea. Electronic address: soohong@cha.ac.kr.
Soo-Hong
SH
Lee
School of Integrative Engineering, Chung-Ang University, Seoul, Republic of Korea. Electronic address: heyshoo@gmail.com.
Hansoo
H
Park
D000818:Animals; D002462:Cell Membrane; D016503:Drug Delivery Systems; D006801:Humans; D053758:Nanoparticles